Natixis Advisors, L.P. Pacira Bio Sciences, Inc. Transaction History

Natixis Advisors, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$25.5 - $31.51 $10,302 - $12,730	-404 Reduced 3.42%	11,413 $327,000
Q1 2024 Apr 25, 2024	BUY	$27.7 - $35.48 $327,330 - $419,267	11,817 New	11,817 $345,000
Q2 2023 Aug 15, 2023	BUY	$36.12 - $47.5 $59,164 - $77,805	1,638 Added 15.82%	11,993 $481,000
Q1 2023 May 11, 2023	BUY	$35.53 - $43.38 $367,913 - $449,199	10,355 New	10,355 $423,000
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $641,268 - $737,008	12,515 New	12,515 $666,000
Q2 2022 Aug 12, 2022	SELL	$51.49 - $81.64 $664,118 - $1.05 Million	-12,898 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$60.03 - $76.49 $142,931 - $182,122	2,381 Added 22.64%	12,898 $984,000
Q4 2021 Feb 08, 2022	BUY	$47.97 - $62.21 $504,500 - $654,262	10,517 New	10,517 $633,000
Q4 2020 Feb 12, 2021	SELL	$50.47 - $66.26 $1.94 Million - $2.55 Million	-38,528 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$51.97 - $63.0 $98,431 - $119,322	1,894 Added 5.17%	38,528 $2.32 Million
Q2 2020 Aug 11, 2020	BUY	$30.8 - $52.47 $469,022 - $799,013	15,228 Added 71.14%	36,634 $1.92 Million
Q1 2020 Apr 27, 2020	BUY	$28.4 - $50.7 $607,930 - $1.09 Million	21,406 New	21,406 $718,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.